The Therapeutic Potential of Abcirximab (c7E3 Fab) in Percutaneous Transluminal Coronary Angioplasty

This publication has 26 references indexed in Scilit:

• A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty.
  Circulation, 1991
• von Willebrand Factor and platelet interactions with the vessel wall
  Blood Coagulation & Fibrinolysis, 1991
• Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors.
  Circulation, 1989
• Antiplatelet monoclonal F(ab′)2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart
  Journal of Molecular and Cellular Cardiology, 1989
• Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.
  Journal of Clinical Investigation, 1988
• Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.
  Circulation, 1988
• Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty
  The American Journal of Cardiology, 1987
• Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model
  Blood, 1986
• Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes
  Journal of the American College of Cardiology, 1986
• Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor
  Blood, 1985